Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

Pegasys

- PMLiVE

First generic version of Teva’s Copaxone cleared by FDA

Will be marketed as Glatopa by Momenta and Novartis’ Sandoz subsidiary

- PMLiVE

Gilead under fire for Sovaldi anti-diversion policy

Accused as generic versions of the drug start to reach the market

Roche Basel Switzerland

Trials of Roche’s new blindness candidate now underway

Lampalizumab in phase III for age-related maculardegeneration

- PMLiVE

Avastin approved for cervical cancer in EU

Was approved for the same indication in the US last summer

- PMLiVE

Amgen gets EU nod for wider use of Vectibix

US biotech’s cancer therapy can now be used in a first-line setting

- PMLiVE

The BMJ weighs in on Avastin/Lucentis debate

The UK’s leading medical journal says Avastin should be used for wet AMD to cut costs

Seismic shifts: Hepatitis C and payers

How hep C is causing paradigm changes in payer behaviour

- PMLiVE

The end of hepatitis C?

Next-gen hep C therapies may see the disease's global elimination - but treament access must be stepped up dramatically

- PMLiVE

NICE gives nod to blood cancer drug Gazyvaro

Roche’s leukaemia drug to be used in combination with chemotherapy

- PMLiVE

Hepatitis C drugs drive US drug costs up in 2014

Played a role in a 13% increase in US prescription spending

Eli Lilly HQ

German court overturns patent on Lilly blockbuster Alimta

Verdict means Actavis can launch generic after December

EU flag

New cancer meds and drug extensions top CHMP recommendations

Drugs for rare disease, oncology and diabetes top regulator’s endorsements

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links